Approval of the vasopressin V2 receptor antagonist tolvaptan—based on the landmark
TEMPO 3: 4 trial—marked a transformation in the management of autosomal dominant …

Abstract Recently, the European Medicines Agency approved the use of the vasopressin V2
receptor antagonist tolvaptan to slow the progression of cyst development and renal …

Background and objectives The Tolvaptan Efficacy and Safety in Management of Autosomal
Dominant Polycystic Kidney Disease and Its Outcomes 3: 4 study demonstrated a significant …

Abstract Background In TEMPO 3: 4, the vasopressin V2 receptor antagonist tolvaptan
slowed total kidney volume (TKV) growth and estimated glomerular filtration rate (eGFR) …

Background The course of autosomal dominant polycystic kidney disease (ADPKD) is often
associated with pain, hypertension, and kidney failure. Preclinical studies indicated that …

Abstract Tolvaptan [Jynarque®(USA); Jinarc®(EU, Canada); Samsca®(Japan)] is a highly
selective vasopressin V 2 receptor antagonist approved for the treatment of autosomal …

Results Fifty-one subjects (81%) completed 3 years of tolvaptan therapy; all experienced
adverse events (AEs), with AEs accounting for six of 12 withdrawals. Baseline TKV (controls …

Autosomal dominant polycystic kidney disease (ADPKD) is an inherited multisystem
disorder, characterized by renal and extra-renal fluid-filled cyst formation and increased …

In the past, the treatment of autosomal dominant polycystic kidney disease (ADPKD) has
been limited to the management of its symptoms and complications. Recently, the US Food …

Background In a previous trial involving patients with early autosomal dominant polycystic
kidney disease (ADPKD; estimated creatinine clearance,≥ 60 ml per minute), the …